A drug called Dysport has been approved for use in adults to treat upper limb spasticity in the U.S., but its use is not allowed in children. A new ruling in the UK may give regulators cause to re-examine their findings. Cerebral Palsy News Today reports.
Birth Injury Lawyer Near Me 1-800-222-9529
The equivalent of the FDA in the UK, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Dysport for the use of upper limb spasticity in children with cerebral palsy. This drug is a variation of the botulinum toxin, a highly-dangerous toxin that, in minute doses, has proved useful in helping with muscle issues.
It is now legal to use Dysport for both upper and lower limb spasticity in the country. A study of 210 children from 2-17 with cerebral palsy gave the agency the findings they needed to make the ruling. Reported side effects included sore throats and upper respiratory infections.
Dysport is a cheaper version of Botox, which is commonly used to treat spasticity in cerebral palsy patients. Now that the drug has been approved for both upper and lower limb spasticity, doctors there can use a single drug to treat spasticity in children.
Untreated spasticity can cause muscle shortening and physical deformities. We hope that this treatment will be approved here in the U.S. thanks to this additional study.